1
|
Li S, Jiang M, Yang L, Zheng F, Liu J, Situ X, Liu X, Weipeng L, Fu B. Identification of platinum resistance-related gene signature for prognosis and immune analysis in bladder cancer. Front Genet 2023; 14:1062060. [PMID: 36777726 PMCID: PMC9908994 DOI: 10.3389/fgene.2023.1062060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Accepted: 01/16/2023] [Indexed: 01/27/2023] Open
Abstract
Purpose: Currently, there is limited knowledge about platinum resistance-related long non-coding RNAs (lncRNAs) in bladder cancer. We aim to identify platinum resistance-related lncRNAs and construct a risk model for accurate prognostic prediction of bladder cancer. Methods: Transcriptomic and clinical data were extracted from The Cancer Genome Atlas (TCGA) database, and platinum resistance-related genes were obtained from HGSOC-Platinum. The platinum resistance-related lncRNAs were obtained by the Spearman correlation analysis. Then, we constructed a risk score model through Cox regression analysis and the LASSO algorithm. The model was verified by analyzing the median risk score, Kaplan-Meier curve, receiver operating characteristic (ROC) curve, and heatmap. We also developed a nomogram and examined the relationship between the risk score model, immune landscape, and drug sensitivity. Lastly, we assessed the differential expression of PRR-lncRNAs in the cisplatin-resistant bladder cancer cell line and the normal bladder cancer cell line using qRT-PCR. Results: We developed and validated an eight-platinum resistance-related lncRNA risk model for bladder cancer. The risk model showed independent prognostic significance in univariate and multivariate Cox analyses. Based on multivariate analysis, we developed a nomogram. The modified model is both good predictive and clinically relevant after evaluation. Furthermore, immune-related and drug-sensitivity analyses also showed significant differential expression between high and low-risk groups. The qRT-PCR demonstrated that most of the lncRNAs were upregulated in cisplatin-resistance cancerous tissues than in control tissues. Conclusion: We have developed a predictive model based on eight platinum resistance-related lncRNAs, which could add meaningful information to clinical decision-making.
Collapse
Affiliation(s)
- Sheng Li
- Department of Urology, Nanchang, China,The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Ming Jiang
- Department of Urology, Nanchang, China,The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Lin Yang
- Department of Urology, Nanchang, China,The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Fucun Zheng
- Department of Urology, Nanchang, China,The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Jiahao Liu
- Department of Urology, Nanchang, China,The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Xiong Situ
- Department of Urology, Nanchang, China,The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Xiaoqiang Liu
- Department of Urology, Nanchang, China,The First Affiliated Hospital of Nanchang University, Nanchang, China,*Correspondence: Bin Fu, ; Xiaoqiang Liu,
| | - Liu Weipeng
- Department of Urology, Nanchang, China,The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Bin Fu
- Department of Urology, Nanchang, China,The First Affiliated Hospital of Nanchang University, Nanchang, China,*Correspondence: Bin Fu, ; Xiaoqiang Liu,
| |
Collapse
|